Lakefront Biotherapeutics NV
GLPGF
$26.24
-$1.84-6.55%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | -202.24% | -202.24% |
| Total Depreciation and Amortization | -- | -- | -- | 3,306.87% | 3,306.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | 178.43% | 178.43% |
| Change in Net Operating Assets | -- | -- | -- | 80.43% | 80.43% |
| Cash from Operations | -- | -- | -- | 25.92% | 25.92% |
| Capital Expenditure | -- | -- | -- | -6.00% | -6.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 181.81% | 181.81% |
| Other Investing Activities | -- | -- | -- | -23.24% | -23.24% |
| Cash from Investing | -- | -- | -- | -20.90% | -20.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 21.65% | 21.65% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 23.08% | 23.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -746.42% | -746.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | 97.24% | 97.24% |